Bridging the Gaps in Breast Cancer

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.